---
title: "Sinobioway Medicine's subsidiary plans to acquire a 51% stake in Traditional Chinese Medicine enterprise Gukan Pharmaceutical"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/245879699.md"
description: "Sinobioway Medicine's wholly-owned subsidiary, Peking University Sinobioway (Shanghai) Biopharmaceutical Co., Ltd., plans to increase its investment in Sichuan Gukang Pharmaceutical by 45 million yuan to acquire a 51% stake. Gukang Pharmaceutical is a mature enterprise in traditional Chinese medicine materials and decoction pieces, with a stable market share and customer resources. This transaction will enhance Sinobioway Medicine's synergy and core competitiveness in the pharmaceutical field"
datetime: "2025-06-24T11:05:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/245879699.md)
  - [en](https://longbridge.com/en/news/245879699.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/245879699.md)
---

# Sinobioway Medicine's subsidiary plans to acquire a 51% stake in Traditional Chinese Medicine enterprise Gukan Pharmaceutical

According to the announcement from Zhitong Finance APP, Sinobioway Medicine (002581.SZ) stated that its wholly-owned subsidiary Peking University Sinobioway (Shanghai) Biopharmaceutical Co., Ltd. (referred to as "Shanghai Sinobioway") plans to increase its investment in Sichuan Gukang Pharmaceutical Co., Ltd. (referred to as "Gukang Pharmaceutical") by RMB 45 million to acquire a 51% stake in Gukang Pharmaceutical.

The announcement stated that the target company, as a traditional Chinese medicine material and decoction piece enterprise with a mature commercialization system, possesses a certain market share and stable customer resources, which is complementary to the company's existing business in terms of channel networks and product types. This transaction will help the company form a synergistic effect in the upstream and downstream of the pharmaceutical field, while enhancing the company's core competitiveness

### Related Stocks

- [002581.CN](https://longbridge.com/en/quote/002581.CN.md)

## Related News & Research

- [Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial](https://longbridge.com/en/news/287276752.md)
- [14:47 ET6th Annual Midwest Design Awards Entry Period Now Open](https://longbridge.com/en/news/286808240.md)
- [BRIEF-Mexico's Fibra Next Extends, Raises Public Offer For Fibra Macquarie](https://longbridge.com/en/news/287128862.md)
- [858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting](https://longbridge.com/en/news/287275117.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)